411 related articles for article (PubMed ID: 26700204)
21. Characteristics of germline mutations in Korean patients with pheochromocytoma/paraganglioma.
Kim JH; Kim MJ; Kong SH; Kim SJ; Kang H; Shin CS; Park SS; Lee KE; Seong MW
J Med Genet; 2022 Jan; 59(1):56-64. PubMed ID: 33219105
[TBL] [Abstract][Full Text] [Related]
22. Gain-of-function mutations in DNMT3A in patients with paraganglioma.
Remacha L; Currás-Freixes M; Torres-Ruiz R; Schiavi F; Torres-Pérez R; Calsina B; Letón R; Comino-Méndez I; Roldán-Romero JM; Montero-Conde C; Santos M; Pérez LI; Pita G; Alonso MR; Honrado E; Pedrinaci S; Crespo-Facorro B; Percesepe A; Falcioni M; Rodríguez-Perales S; Korpershoek E; Ramón-Maiques S; Opocher G; Rodríguez-Antona C; Robledo M; Cascón A
Genet Med; 2018 Dec; 20(12):1644-1651. PubMed ID: 29740169
[TBL] [Abstract][Full Text] [Related]
23. Activating FGFR1 Mutations in Sporadic Pheochromocytomas.
Welander J; Łysiak M; Brauckhoff M; Brunaud L; Söderkvist P; Gimm O
World J Surg; 2018 Feb; 42(2):482-489. PubMed ID: 29159601
[TBL] [Abstract][Full Text] [Related]
24. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.
Neumann HP; Pawlu C; Peczkowska M; Bausch B; McWhinney SR; Muresan M; Buchta M; Franke G; Klisch J; Bley TA; Hoegerle S; Boedeker CC; Opocher G; Schipper J; Januszewicz A; Eng C;
JAMA; 2004 Aug; 292(8):943-51. PubMed ID: 15328326
[TBL] [Abstract][Full Text] [Related]
25. Somatic IDH1 Hotspot Variants in Chinese Patients With Pheochromocytomas and Paragangliomas.
Li M; He Y; Pang Y; Zhang J; Feng Y; He Y; Xu X; Wei Y; Zhong D; Deng W; Wang L; Yan B; Jiang Y; Xu N; Cai H; Wen Y; Ning J; Liu Y; Gao X; Shan Z; Liu L; Teng X; Richter S; Jiang J
J Clin Endocrinol Metab; 2023 Apr; 108(5):1215-1223. PubMed ID: 36355572
[TBL] [Abstract][Full Text] [Related]
26. Disentangling of Malignancy from Benign Pheochromocytomas/Paragangliomas.
Kim KY; Kim JH; Hong AR; Seong MW; Lee KE; Kim SJ; Kim SW; Shin CS; Kim SY
PLoS One; 2016; 11(12):e0168413. PubMed ID: 27992508
[TBL] [Abstract][Full Text] [Related]
27. Genetic Characteristics of Incidental Pheochromocytoma and Paraganglioma.
Zhang J; Li M; Pang Y; Wang C; Wu J; Cheng Z; Li X; Lu Z; Liu Y; Guo J; Chen X; He Y; Guan X; Xu X; Wang Y; Liu J; Guo W; Hou Y; Liu L; Jiang J; Gao X
J Clin Endocrinol Metab; 2022 Apr; 107(5):e1835-e1842. PubMed ID: 35106577
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
[TBL] [Abstract][Full Text] [Related]
29. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
[TBL] [Abstract][Full Text] [Related]
30. Cost-minimization analysis of sequential genetic testing versus targeted next-generation sequencing gene panels in patients with pheochromocytoma and paraganglioma.
Pipitprapat W; Pattanaprateep O; Iemwimangsa N; Sensorn I; Panthan B; Jiaranai P; Chantratita W; Sorapipatcharoen K; Poomthavorn P; Mahachoklertwattana P; Sura T; Tunteeratum A; Srichan K; Sriphrapradang C
Ann Med; 2021 Dec; 53(1):1243-1255. PubMed ID: 34309460
[TBL] [Abstract][Full Text] [Related]
31. Pheo-Type: A Diagnostic Gene-expression Assay for the Classification of Pheochromocytoma and Paraganglioma.
Flynn A; Dwight T; Harris J; Benn D; Zhou L; Hogg A; Catchpoole D; James P; Duncan EL; Trainer A; Gill AJ; Clifton-Bligh R; Hicks RJ; Tothill RW
J Clin Endocrinol Metab; 2016 Mar; 101(3):1034-43. PubMed ID: 26796762
[TBL] [Abstract][Full Text] [Related]
32. Transcriptome Analysis of lncRNAs in Pheochromocytomas and Paragangliomas.
Job S; Georges A; Burnichon N; Buffet A; Amar L; Bertherat J; Bouatia-Naji N; de Reyniès A; Drui D; Lussey-Lepoutre C; Favier J; Gimenez-Roqueplo AP; Castro-Vega LJ
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31678991
[TBL] [Abstract][Full Text] [Related]
33. Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas.
Fishbein L; Khare S; Wubbenhorst B; DeSloover D; D'Andrea K; Merrill S; Cho NW; Greenberg RA; Else T; Montone K; LiVolsi V; Fraker D; Daber R; Cohen DL; Nathanson KL
Nat Commun; 2015 Jan; 6():6140. PubMed ID: 25608029
[TBL] [Abstract][Full Text] [Related]
34. Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas.
Castro-Vega LJ; Buffet A; De Cubas AA; Cascón A; Menara M; Khalifa E; Amar L; Azriel S; Bourdeau I; Chabre O; Currás-Freixes M; Franco-Vidal V; Guillaud-Bataille M; Simian C; Morin A; Letón R; Gómez-Graña A; Pollard PJ; Rustin P; Robledo M; Favier J; Gimenez-Roqueplo AP
Hum Mol Genet; 2014 May; 23(9):2440-6. PubMed ID: 24334767
[TBL] [Abstract][Full Text] [Related]
35. The genomic landscape of phaeochromocytoma.
Flynn A; Benn D; Clifton-Bligh R; Robinson B; Trainer AH; James P; Hogg A; Waldeck K; George J; Li J; Fox SB; Gill AJ; McArthur G; Hicks RJ; Tothill RW
J Pathol; 2015 May; 236(1):78-89. PubMed ID: 25545346
[TBL] [Abstract][Full Text] [Related]
36. Pheochromocytoma and paraganglioma: molecular testing and personalized medicine.
Burnichon N; Buffet A; Gimenez-Roqueplo AP
Curr Opin Oncol; 2016 Jan; 28(1):5-10. PubMed ID: 26599293
[TBL] [Abstract][Full Text] [Related]
37. New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas.
Toledo RA
Endocr Relat Cancer; 2017 Sep; 24(9):C9-C19. PubMed ID: 28667082
[TBL] [Abstract][Full Text] [Related]
38. Pheochromocytoma: When to search a germline defect?
Buffet A; Burnichon N; Amar L; Gimenez-Roqueplo AP
Presse Med; 2018; 47(7-8 Pt 2):e109-e118. PubMed ID: 30100270
[TBL] [Abstract][Full Text] [Related]
39. H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.
Gong L; Bui MM; Zhang W; Sun X; Zhang M; Yi D
Histol Histopathol; 2021 Jan; 36(1):61-68. PubMed ID: 33021329
[TBL] [Abstract][Full Text] [Related]
40. Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma.
Korpershoek E; Petri BJ; van Nederveen FH; Dinjens WN; Verhofstad AA; de Herder WW; Schmid S; Perren A; Komminoth P; de Krijger RR
Endocr Relat Cancer; 2007 Jun; 14(2):453-62. PubMed ID: 17639058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
